ArticleInternational journal of nanomedicine2026
Lipid Co-Loaded with PGRN and NATA Demonstrated Significantly Enhanced Antifungal and Anti-Inflammatory Activities in the Treatment of Fungal Keratitis.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop a lipid nanoplatform, designated as "PGRN-NATA-LN", for the co-encapsulation of Natamycin (NATA) and Progranulin (PGRN), and to evaluate its efficacy and safety in the treatment of fungal keratitis (FK). Methods: The characterization of PGRN-NATA-LN was carried out using a Malvern laser particle size analyzer and transmission electron microscopy (TEM). The drug's encapsulation efficiency, loading capacity, and release profile were evaluated through liquid chromatography, ultraviolet spectrophotometry, and ELISA. The cytotoxicity, ocular surface toxicity, and systemic safety of PGRN-NATA-LN were also examined. In vitro studies were performed to investigate the antifungal properties of PGRN-NATA-LN. Furthermore, cell-based assays were conducted to determine the capability of PGRN-NATA-LN to induce macrophage polarization. Results: The particle size of PGRN-NATA-LN is approximately 140 nm, demonstrating a significant loading capacity for both PGRN and NATA. This facilitates the gradual release of NATA and PGRN, thereby reducing the clearance from the ocular surface. In vitro studies have confirmed the potent antifungal activity and anti-inflammatory of PGRN-NATA-LN. Furthermore, in vivo studies demonstrated that PGRN-NATA-LN exhibited superior therapeutic efficacy in treating FK. Discussion: The PGRN-NATA-LN approach represents a promising strategy to enhance drug bioavailability, demonstrating significant potential in the treatment of FK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.